Platinum-based chemotherapy is believed to be more effective in these cases due to the rapid tumor proliferation and greater dependency on DNA repair pathways, which are disrupted by platinum agents, including temozolomide alone or in combination with capecitabine (CAPTEM), which are generally considered for second-line treatment, particularly in patients with a lower Ki-67 index or contraindications to platinum agents. The gene discussed is MKI67; the disease is neoplasm.